Follow our news on LinkedIn

Learn more
Oncodesign Precision Medicine Stand with Ukraine

Follow our news on LinkedIn

Learn more
  • Our pipeline
    • OPM 101
    • OPM 102
    • OPM 201
    • COMETE
    • Partnering
    • Scientific news
  • Our innovation technologies
    • OncoSNIPER
    • Nanocyclix®
    • PROMETHE®
  • Investors
    • Message from the President
    • Investor Day 2023
    • Regulated informations [FR]
    • Press Releases
    • General Meetings [FR]
  • About us
    • Latest news
    • Our history
    • Management
    • Our HR policy
    • Our CSR approach
    • FederAidd
    • PROMETHE ®
  • Contact us
  • Français
  • English

Posts

  • You are currently browsing the Oncodesign Precision Medicine blog archives for April 2024.

  • Pages

    • About us
      • Careers
      • FederAidd
      • Management
      • News
      • Our CSR approach
      • Our history
    • Contact us
    • Home
    • Investors
      • Message from the President
      • Regulated informations [FR]
      • Investor Day 2023
    • Legal notice
    • Our innovation technologies
      • Nanocyclix
      • OncoSNIPER
      • PROMETHE ®
    • Our pipeline
      • OPM 101
      • OPM 102
      • Partnering
      • OPM 201
      • COMETE
      • Scientific news
    • Personal data policy
    • Press Releases
    • Thank you for signing up to our newsletter
    • Thank you for your message.

  • Archives

    • September 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • October 2023
    • May 2023
    • April 2023
    • February 2023
    • December 2022
    • October 2022
    • September 2022
    • July 2022
    • June 2022
    • March 2022
    • February 2022
    • January 2022
    • October 2021
    • June 2021
    • May 2021
    • September 2020
    • October 2019

  • Categories

    • Financial (13)
    • News (22)
    • Poster (3)
    • Press Release (25)
    • Scientific paper (4)
    • Uncategorized (1)
Oncodesign Precision Medicine
  • Our innovation technologies
    • OncoSNIPER
    • Nanocyclix
    • PROMETHE
  • Our pipeline
  • Latest News
  • About us
  • Investors
  • Contact us

Newsletter

  • Legal notice
  • Personal data policy